Literature DB >> 2136742

The amino terminus of muscle tropomyosin is a major determinant for function.

Y J Cho1, J Liu, S E Hitchcock-DeGregori.   

Abstract

The amino-terminal region of muscle tropomyosin is highly conserved among muscle and 284-residue non-muscle tropomyosins. Analysis of fusion and nonfusion striated alpha-tropomyosins and a mutant in which residues 1-9 have been deleted has shown that the amino terminus is crucial for function. The presence of 80 amino acids of a nonstructural influenza virus protein (NS1) on the amino terminus of tropomyosin allows magnesium-independent binding of tropomyosin to actin. The fusion tropomyosin inhibits the actomyosin S1 ATPase at all myosin S1 concentrations tested, indicating that the presence of the fusion peptide prevents myosin S1 from switching the actin filament from the inhibited to the potentiated state. Nonfusion tropomyosin, an unacetylated form, has no effect on the actomyosin S1 ATPase, though it regulates normally with troponin. Deletion of residues 1-9, which are believed to overlap with the carboxyl-terminal end of tropomyosin in the thin filament, results in loss of tropomyosin function. The mutant is unable to bind to actin, in the presence and absence of troponin, and it has no regulatory function. The removal of the first 9 residues of tropomyosin is much more deleterious than removal of the last 11 by carboxypeptidase digestion. We suggest that the structure of the amino-terminal region and acetylation of the initial methionine are crucial for tropomyosin function.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2136742

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

Review 1.  Vertebrate tropomyosin: distribution, properties and function.

Authors:  S V Perry
Journal:  J Muscle Res Cell Motil       Date:  2001       Impact factor: 2.698

2.  Tropomyosin requires an intact N-terminal coiled coil to interact with tropomodulin.

Authors:  Norma J Greenfield; Velia M Fowler
Journal:  Biophys J       Date:  2002-05       Impact factor: 4.033

3.  Structure and interactions of the carboxyl terminus of striated muscle alpha-tropomyosin: it is important to be flexible.

Authors:  Norma J Greenfield; Thomas Palm; Sarah E Hitchcock-DeGregori
Journal:  Biophys J       Date:  2002-11       Impact factor: 4.033

4.  Electron microscopy and persistence length analysis of semi-rigid smooth muscle tropomyosin strands.

Authors:  Duncan Sousa; Anthony Cammarato; Ken Jang; Philip Graceffa; Larry S Tobacman; Xiaochuan Edward Li; William Lehman
Journal:  Biophys J       Date:  2010-08-04       Impact factor: 4.033

5.  Erythrocyte tropomodulin isoforms with and without the N-terminal actin-binding domain.

Authors:  Weijuan Yao; Lanping Amy Sung
Journal:  J Biol Chem       Date:  2010-07-30       Impact factor: 5.157

6.  Localization of the binding interface between leiomodin-2 and α-tropomyosin.

Authors:  Mert Colpan; Dmitri Tolkatchev; Samantha Grover; Gregory L Helms; John R Cort; Natalia Moroz; Alla S Kostyukova
Journal:  Biochim Biophys Acta       Date:  2016-02-09

Review 7.  Gestalt-binding of tropomyosin to actin filaments.

Authors:  Kenneth C Holmes; William Lehman
Journal:  J Muscle Res Cell Motil       Date:  2008-12-31       Impact factor: 2.698

8.  Some binding properties of Omp T digested muscle tropomyosin.

Authors:  Charitha L Goonasekara; Lisa J Gallivan; Donna M Jackman; David H Heeley
Journal:  J Muscle Res Cell Motil       Date:  2007-09-06       Impact factor: 2.698

9.  Cloning of tropomyosins from lobster (Homarus americanus) striated muscles: fast and slow isoforms may be generated from the same transcript.

Authors:  D L Mykles; J L Cotton; H Taniguchi; K Sano; Y Maeda
Journal:  J Muscle Res Cell Motil       Date:  1998-02       Impact factor: 2.698

10.  Transformation-related expression of a low-molecular-mass tropomyosin isoform TM5/TM30nm in transformed rat fibroblastic cell lines.

Authors:  K Miyado; M Sato; S Taniguchi
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.